Format

Send to

Choose Destination
Cancer. 2016 Feb 1;122(3):367-77. doi: 10.1002/cncr.29769. Epub 2015 Nov 5.

Immunotherapy in hepatocellular carcinoma: Primed to make a difference?

Author information

1
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
2
Weill Cornell Medical College, New York, New York.
3
Internal Medicine/Hematology and Oncology, American University of Beirut, Beirut, Lebanon.

Abstract

Advanced hepatocellular carcinoma (HCC) carries a dismal prognosis and the current treatment is limited to sorafenib, an agent with modest benefit. Preclinical data have indicated that several immunologic mechanisms are at play to promote HCC development and growth while impairing effective antitumor immune surveillance. Several novel approaches geared toward manipulating the immune response to HCC have suggested a therapeutic benefit in early-stage clinical trials, indicating a real potential to augment tumor-specific immunity and improve outcomes in patients with this disease. In the current study, the authors reviewed the barriers to an effective immune response against HCC and contemporary clinical investigations that may be "primed" to alter the natural history of HCC.

KEYWORDS:

checkpoint inhibitors; hepatocellular carcinoma; immune evasion; immunotherapy

PMID:
26540029
DOI:
10.1002/cncr.29769
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center